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Introduction: Innate immune suppression occurs commonly in pediatric critical illness, in which it is associated
with adverse outcomes. Less is known about the adaptive immune response in critically ill children with sepsis. We
designed a single-center prospective, observational study to test the hypothesis that children with septic shock
would have decreased adaptive immune function compared with healthy children and that among children with
sepsis, lower adaptive immune function would be associated with the development of persistent infection or new
nosocomial infection.
Methods: Children (18 years or younger) who were admitted to the pediatric intensive care unit with septic shock
(by International Consensus Criteria) were enrolled in the study. Blood samples were taken within 48 hours of sepsis
onset and again on Day 7 of illness. Adaptive immune function was assessed with ex vivo phytohemagglutinin
(PHA)-induced cytokine production capacity of isolated CD4+ T cells. Percentage of regulatory T cells was measured
with flow cytometry. Absolute lymphocyte counts were recorded when available.
Results: In total, 22 children with septic shock and eight healthy controls were enrolled. Compared with those
from healthy children, CD4+ T cells isolated from septic shock children on Days 1 to 2 of illness and stimulated with
PHA produced less of the pro-inflammatory cytokine interferon gamma (IFN-γ) (P = 0.002), and the antiinflammatory
cytokines interleukin (IL)-4 (P = 0.03) and IL-10 (P = 0.02). Among septic shock children, those who went on to
develop persistent or nosocomial infection had decreased T-cell ex vivo PHA-induced production of IFN-γ (P = 0.01),
IL-2 (P = 0.01), IL-4 (P = 0.008), and IL-10 (P = 0.001) compared with septic shock children who did not. Percentage of
regulatory T cells (CD4+CD25+CD127lo) did not differ among groups.
Conclusions: Adaptive immune suppression may occur early in the course of pediatric septic shock and is
associated with adverse infection-related outcomes.Introduction
Despite improvements in critical care, sepsis continues to
be an important source of morbidity and mortality in chil-
dren [1,2]. Successful recovery from sepsis requires reso-
lution of initial infection and prevention of new nosocomial
infections. Whereas an intact immune response is re-
quired to combat infection, critically ill adults and children* Correspondence: jennifer.muszynski@nationwidechildrens.org
1Division of Critical Care Medicine, Nationwide Children’s Hospital, 700
Children’s Drive, Columbus, OH 43205, USA
2The Research Institute at Nationwide Children’s Hospital, Columbus, OH
43205, USA
Full list of author information is available at the end of the article
© 2014 Muszynski et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.commonly demonstrate immune suppression. In critic-
ally ill children, innate immune suppression (for example,
monocyte function) has been described across a broad
range of diagnoses, including sepsis, where it is associated
with increased risks of mortality and nosocomial infection
[3-6]. Previous studies suggest that both innate and adap-
tive immune suppression may commonly occur in adults
with sepsis, associated with poor outcomes [7-11].
CD4+ T-helper cells are an integral cell type in the adap-
tive immune response. Adult studies demonstrate alter-
ations in CD4+ T cells in septic shock patients compared
with nonseptic controls, including increased lymphocyte
apoptosis; decreased proliferative capacity in response toral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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flammatory cytokine responses (for example, TH2); and
increased percentage of immunosuppressive regulatory T
cells (Treg) [9,12-15]. Further, these antiinflammatory
T-cell phenotypes in adults are associated with increased
risks of sepsis-related mortality [10,15]. Gene-expression
studies in both adults and children likewise suggest down-
regulation of adaptive immune responses in sepsis [16-18].
Functional analyses of the adaptive immune response
in septic shock children are lacking, and relationships
between adaptive immune function and outcomes are un-
known in this population.
We designed a prospective, observational study to test
the hypothesis that suppressed adaptive immune function,
measured with ex vivo CD4+ T-cell cytokine production
capacity, would be associated with the development of
persistent or nosocomial infection in children with septic
shock. We further hypothesized that septic shock children
would have increased percentage of Treg among CD4+ T
cells compared with healthy children, and that among sep-
tic shock children, an increased percentage of Treg would




The pediatric intensive care unit (PICU) at Nationwide
Children’s Hospital is a 40-bed, mixed medical-surgical,
quaternary care unit with more than 2,000 admissions
annually. Patients admitted to a separate cardiothoracic
intensive care unit were not included in this study. The
study was approved by the institutional review board at
Nationwide Children’s Hospital. Informed consent pro-
vided by the parent or guardian and, where appropriate,
assent provided by the patient were obtained for all sub-
jects before study enrollment.
Subjects
Patients younger than 18 years were prospectively enrolled
after admission to the PICU at Nationwide Children’s
Hospital with a diagnosis of septic shock, as defined by
International Consensus Criteria [19]. Subjects were ex-
cluded if they had a weight of less than 3.5 kg, a white
blood cell count less than 1,000 cells/mm3, a limitation-
of-care order in place, or a high likelihood of progression
to brain death (as determined by the primary treatment
team). These exclusion criteria were chosen to enroll pa-
tients for whom blood samples could be safely obtained,
who would have leukocytes available for study, and who
would likely survive for the duration of a 7-day sampling
window. Healthy control subjects were enrolled from
the outpatient phlebotomy area. Healthy subjects were
excluded if they had fever, a history of chronic inflamma-
tory disease, transplant or malignancy, or were currentlytaking treatment doses of antibiotics or immunosup-
pressive medications (including systemic corticosteroids
within the past month or nonsteroidal antiinflammatory
medications within the past 48 hours).
Patient sampling
For sepsis patients, blood samples were collected within
48 hours of the onset of septic shock and again on Day
7 of illness. Day 7 samples were not obtained from pa-
tients who were no longer in the hospital or who no lon-
ger had an indwelling vascular catheter for painless blood
draws. Blood samples were collected once from healthy
control subjects. Samples for cell isolation and flow cy-
tometry were drawn in EDTA tubes. Samples for whole-
blood endotoxin stimulation studies and plasma cytokines
were drawn in heparin tubes (Becton Dickinson). All sam-
ples were kept on ice and processed within 30 minutes of
collection. Absolute lymphocyte counts were calculated
from complete blood cell count with differential tests per-
formed as part of routine clinical care.
CD4+ T-cell isolation and adaptive immune function
To evaluate adaptive immune function, CD4+ T cells were
isolated and stimulated as follows. Peripheral blood mono-
nuclear cells were collected with density gradient centrifuga-
tion by using lymphocyte-separation medium (Mediatech,
Manassas, VA, USA). CD4+ T cells were then isolated with
negative selection by using magnetic beads (Miltenyi
Biotec, Auburn, CA, USA). T cells, 5 × 105 CD4+, were in-
cubated for 24 hours at 37°C in complete media (RPMI +
10% fetal bovine serum + 1% penicillin/streptomycin) in
the presence or absence of 10 μg/ml of phytohemagglu-
tinin (PHA) (Sigma, St. Louis, MO, USA). After 24 hours,
the supernatant was collected and stored at −80°C for sub-
sequent cytokine analysis. Production of the cytokines
IL-2, IL-4, IL-10, and IFN-γ from stimulated cells was de-
termined with multiplex immunoassay (Bio-Rad, Hercules,
CA, USA).
Percentage of regulatory T cells (CD4+, CD25+, CD127lo)
among freshly isolated, unstimulated CD4+ T cells was
determined with flow cytometry. The following anti-
bodies were used: FITC anti-human CD4, APC anti-human
CD25, and PE anti-human CD127 (Becton Dickinson).
Data were acquired on an LSRII cytometer (Becton
Dickinson) and analyzed by using FlowJo software (TreeStar,
Ashland, OR, USA).
Plasma cytokines and innate immune function
Plasma from blood drawn in heparin tubes was obtained
and stored at −80°C for subsequent quantification of cir-
culating plasma IL-6, IL-8, and IL-10. Innate immune
function was assessed with whole-blood ex vivo lipopoly-
saccharide (LPS)-induced tumor necrosis factor (TNF)α
production capacity as follows. Within 30 minutes of
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prepared stimulation tubes and incubated for 4 hours at
37°C. The stimulation tubes contain 0.5 ng/ml LPS (phe-
nol-extracted from Salmonella abortus equii (Sigma).
After 4 hours, the supernatant was collected and stored
at −80°C for subsequent cytokine analysis. Stimulation
studies were performed in duplicate, with average values
reported. Cytokine production from unstimulated plasma
samples and from stimulated whole blood was quanti-
fied with chemiluminescence by using the Immulite auto-
mated chemiluminometer (Siemens Healthcare Diagnostics,
Deerfield, IL, USA). Severe innate immune suppression
was defined as an ex vivo LPS-induced TNF-α production
capacity of less than 250 pg/ml, based on our previous
studies of critically ill children [3,4].
Definitions and statistical analysis
Clinical data were obtained from the electronic medical
record. Severity of illness was determined with pediatric
risk of mortality (PRISM III), pediatric logistic organ dys-
function (PELOD), and organ-failure index (OFI) scoring
within 24 hours of sepsis onset [20-22]. Our primary out-
come measure was the occurrence of either persistent in-
fection or new nosocomial infection. For bloodstream and
urinary tract infections, persistent infection was defined as
consecutive positive blood or urine cultures for greater
than or equal to 7 days. For lower respiratory tract infec-
tions, persistent infection was defined as consecutive posi-
tive endotracheal cultures with ongoing symptoms of
pulmonary infection, including purulent secretions (de-
fined as the presence of white blood cells on Gram stain
of lower respiratory culture); hypoxia or need for invasive
mechanical ventilation; and infiltrate(s) on chest radio-
graphs for greater than or equal to 7 days. For all sites of
infection, initial infection was presumed to be resolved if
subsequent cultures were negative or if the site was not
re-cultured. New nosocomial infection was defined ac-
cording to CDC criteria and included any new bacterial or
fungal infection occurring after 48 hours of sepsis onset
[23]. Daily cultures were not obtained as part of the study
protocol, although it is routine practice in our PICU to
obtain blood, urine, and lower respiratory cultures daily
with any fever and to obtain daily blood cultures in pa-
tients with bacteremia until two consecutive blood cul-
tures are negative. For patients with community-acquired
septic shock, sepsis onset was defined as the time of initial
presentation to the emergency department. For patients
with nosocomial sepsis as their study-enrollment event,
sepsis onset was defined as the time at which the patient
met criteria for septic shock. ICU-free days were deter-
mined based on physical admission to and discharge from
the ICU. Patients who died in the ICU were considered to
have zero ICU-free days. Mortality was defined as death
during hospitalization.Comparisons between groups were analyzed with the
Mann–Whitney U test for continuous variables and the
Fisher Exact test for categoric values. Differences in values
over time were compared between groups by using analysis
of variance. Data are presented as median (interquartile
range). A P value < 0.05 was considered to be significant
throughout. Data were analyzed by using Prism6 software
(GraphPad Inc., La Jolla, CA, USA).
Results
Subjects
We enrolled 22 sepsis patients and eight healthy children.
Healthy subjects had a median age of 12 (3.8 to 14) years
(P = 0.3 versus sepsis patients), and 50% were girls. Demo-
graphic information for sepsis patients is displayed in
Table 1. Among sepsis patients, 36% had a complex chronic
condition, most commonly developmental delay (n = 5).
Two patients in the cohort had an oncologic diagnosis. Nei-
ther patient was leukopenic at the time of sampling, and
neither was receiving chemotherapy at the time of sepsis
onset. No transplant patients were in the cohort. Septic
shock was community acquired in 20 (91%) cases. Of the
18 patients with positive cultures, seven (39%) had gram-
positive infection, four (22%) had gram-negative infection,
three (17%) had mixed bacterial infection, two (11%) had
viral infection, and two (11%) had mixed viral and bacter-
ial infections. All patients were treated with parenteral
antibiotics. All patients with positive growth of bacterial
pathogens received correct antibiotic coverage (based on
susceptibilities of cultured organisms) with a median time
of 2.7 (1.2 to 5.9) hours from sepsis onset to the first dose
of parenteral antibiotic.
Six (27%) patients developed either persistent infection
or new nosocomial infection. No significant differences
in clinical characteristics were found between patients
who developed persistent or new nosocomial infection
and those who did not, with the exception of the use of
methylprednisolone or dexamethasone for greater than
24 hours (Table 1). Overall, 64% of patients were treated
with glucocorticoids within 7 days of sepsis onset. In
the majority of cases, glucocorticoid use consisted of
dexamethasone for less than 24 hours, with the intention
to prevent or treat postextubation stridor. Of the pa-
tients who received methylprednisolone or dexametha-
sone for greater than 24 hours, two patients were treated
with a methylprednisolone infusion for acute respira-
tory distress syndrome; one patient was treated with
methylprednisolone for reactive airways disease; and
one patient was treated with dexamethasone in the set-
ting of meningitis.
Characteristics of patients with persistent (n = 3) or new
nosocomial (n = 3) infection are listed in Table 2. Of the
patients with persistent infection, one patient had persist-
ent pneumonia for 14 days. The other two patients had
Table 1 Patient demographics
Characteristic All Persistent or nosocomial infection, No persistent or nosocomial infection Pa
(n = 22) (n = 6) (n = 16)
Age, years 1.3 [0.3–14] 8 [0.9 – 16] 0.9 [0.2–12] 0.1
Female gender, n (%) 10 (45) 2 (33) 8 (50) 0.6
Complex chronic condition, n (%) 8 (36) 3 (50) 5 (31) 1
Initial OFI≥ 3, n (%)b 10 (45) 5 (83) 5 (31) 0.06
Initial PRISM IIIb 11.5 [9 – 14] 10.5 [8.8 – 12.5] 13 [8 – 16] 0.4
Initial PELODb 12 [11 – 18] 12 [1 – 14] 12 [11 – 21] 0.3
Site of initial infection, n (%)
Culture negative 4 (18) 0 4 (25)
Blood 4 (18) 2 (33) 2 (13)
Lung 8 (36) 3 (50) 5 (31)
Urine 2 (9) 0 2 (13)
Abdomen 1 (5) 0 1 (6)
Multisite 3 (14) 1 (17) 2 (13)
Glucocorticoid use, n (%)c
MP/Dex for < 24 hoursd 8 (36) 1 (17) 7 (44) 0.4
MP/Dex for > 24 hours 4 (18) 3 (50) 1 (6) 0.046
HCTZ for > 24 hoursd 4 (18) 0 4 (25) 0.5
Outcomes
ICU-free days in 28 days 17 [10 – 21] 5.5 [0–16] 19.2 [15 – 22] 0.05
Mortality, n (%) 2 (9) 1 (17) 1 (6) 0.4
aPersistent or nosocomial infection versus no persistent or nosocomial infection (Mann–Whitney or Fisher Exact test). bValues at the time of sepsis onset.
cGlucocorticoid use within 7 days of sepsis onset. dIncludes two patients treated with HCTZ and with MP/Dex for less than 24 hours. PRISM, Pediatric Risk of
Mortality; PELOD, Pediatric Logistic Organ Dysfunction; OFI, Organ Failure Index; MP, methylprednisolone; Dex, dexamethasone; HCTZ, hydrocortisone. Data are
median (IQR), except where otherwise specified.
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three nosocomial infections were diagnosed within 1 month
of sepsis onset, with one infection occurring in the first
week of illness (Day 5) and the other two occurring later
(Day 25 and Day 27).
Systemic cytokines
As expected, for all sepsis patients on days 1 to 2 of ill-
ness, plasma levels of proinflammatory cytokines, IL-6
and IL-8, were significantly elevated compared with healthyTable 2 Characteristics of sepsis patients with persistent or n
Persistent or nosocomial Age (years) Complex chronic condition




Nosocomial 16 SGS, TPN dependence
Nosocomial 0.9 Chromosomal abnormality,
developmental delay
aAt the time of sepsis onset. PRISM, Pediatric risk of mortality; OFI, organ failure indcontrols (82 (21 to 396) pg/ml versus < 6 pg/ml and 50
(19 to 92) pg/ml versus < 15 pg/ml, respectively). Among
sepsis patients, early plasma proinflammatory cytokine
levels tended to be higher in patients who developed per-
sistent or nosocomial infection compared with those who
did not, although this difference did not reach statistical
significance. Early plasma levels of the antiinflammatory
cytokine, IL-10, were significantly higher in patients who
went on to develop persistent or nosocomial infection
(Table 3).osocomial infection
PRISMa III OFI Organism Site
14 3 Pseudomonas Lung
12 4 MRSA Blood
10 3 MRSA Blood, Lung
5 2 Pseudomonas Blood, Lung
10 3 Escherichia coli Pseudomonas Blood
11 3 Enterobacter Lung
ex; SGS, short-gut syndrome; TPN, total parenteral nutrition.
Table 3 Plasma cytokine levels within 48 hours of septic-shock onset
Cytokine Persistent or nosocomial infection, No persistent or nosocomial infection, Healthy controls P
(n = 6) (n = 16) (n = 8)
IL-6 pg/ml 265 (35–792) 82 (15–396) < 6 0.3
IL-8 pg/ml 77 (48–176 42 (17–74) < 15 0.1
IL-10 pg/ml 36 (13–64) 10 (10–29) 10 (10 – 13.9) 0.04
P values are for persistent or nosocomial infection versus no persistent or nosocomial infection (Mann–Whitney). Data are expressed as median (IQR).
Muszynski et al. Critical Care 2014, 18:R145 Page 5 of 10
http://ccforum.com/content/18/4/R145Adaptive immune response
Despite the presence of a systemic inflammatory response
and high levels of circulating cytokines, CD4+ T cells iso-
lated from sepsis patients within 48 hours of sepsis onset
demonstrated significantly reduced ability to produce the
proinflammatory cytokine, IFN-γ, compared with healthy
controls (74 (27 to 146) pg/ml versus 606 (169 to 1,169),
P = 0.002). Early T-cell cytokine-production capacities of
the antiinflammatory cytokines, IL-4 and IL-10, were also
lower in sepsis patients as a whole compared with healthy
controls (2.9 (0.7 to 5) versus 8.2 (3 to 10) pg/ml; P = 0.03;
and 23 (6 to 41) versus 68 (26 to 126) pg/ml, P = 0.02),
respectively.
Among sepsis patients, the development of persistent
or new nosocomial infection was associated with lower
Day 1 to 2 CD4+ T-cell cytokine-production capacities
(Figure 1A-D). This was apparent for each cytokine eval-
uated, including the proinflammatory cytokines (IFN-γ
and IL-2) and antiinflammatory cytokines (IL-10 and IL-4).
For those patients with Day 7 samples available (n = 15),
adaptive immune function tended to improve over time in
both groups (Figure 1E-H).
Innate immune response
Similar to the adaptive immune response, sepsis patients
demonstrated significantly reduced innate immune func-
tion on Days 1 to 2 of illness compared with healthy con-
trols (Figure 2). Early innate immune function did not
differ between those who went on to develop persistent or
nosocomial infection and those who did not (Figure 2).
However, only two patients in the cohort demonstrated
persistent, severe innate immune suppression (ex vivo
TNF-α production capacity < 250 pg/ml on Day 7). Both
of these patients died during their hospitalization com-
pared with zero deaths among patients with Day 7 ex vivo
TNF-α production capacity > 250 pg/ml (P = 0.008; OR,
145; 95% CI, 2.3 to 9,146).
Absolute lymphocyte count and regulatory T cells
To evaluate further the adaptive immune suppression in
sepsis patients, we determined absolute lymphocyte counts
and percentages of Treg. Absolute lymphocyte counts
tended to be lower in sepsis patients compared with healthy
controls. They were lowest for sepsis patients who devel-
oped persistent or new nosocomial infection (Figure 3A, B).Regarding Treg in sepsis patients, the percentage of Treg
was not different between groups on Days 1 to 2 or on
Day 7 (for the smaller cohort of children with Day 7 data
available). Furthermore, sepsis children overall had a simi-
lar percentage of Treg compared with healthy controls
(Figure 3C, D).
Discussion
In this cohort of critically ill children with septic shock,
early adaptive immune suppression, as measured by re-
duced CD4+ T-cell cytokine-production capacity was asso-
ciated with the development of persistent or nosocomial
infection. As cell numbers were controlled for in our ex-
perimental model, this suggests that decreased cellular re-
sponsiveness in addition to lymphopenia may be associated
with adverse infection-related outcomes in this cohort.
The well-recognized signs and symptoms of sepsis are
manifestations of an overwhelming inflammatory response.
However, it is increasingly recognized that counterregula-
tory mediators that impair immune cell responsiveness are
released shortly after (or at the same time as) proinflam-
matory mediators [5,7-9,11,24,25]. This results in a state of
immune suppression, which is an increasingly recognized
sequela of critical illness. In critically ill adults with sepsis,
alterations of both innate and adaptive immune function,
including elevated circulating levels of proinflammatory cy-
tokines, decreased monocyte MHC class II (for example,
HLA-DR) expression, and lymphocyte apoptosis have all
been associated with poor outcomes, suggesting that dys-
regulated immune responses may be important contribu-
tors to morbidity and mortality in the ICU [7,10,11,26].
In critically ill children, innate immune suppression
has been well characterized across a variety of diagnoses
[3-6,27]. In previous studies, the inability of innate im-
mune cells to produce proinflammatory cytokines in re-
sponse to stimulation has been independently associated
with increased risks of mortality and nosocomial infection
in critically ill children with influenza, multiple organ dys-
function, respiratory syncytial virus infection, or after car-
diopulmonary bypass [3-6].
Data regarding the adequacy of the adaptive immune
response in critically ill children are fewer. Two previous
studies evaluated absolute lymphocyte counts in critic-
ally ill children. In one study of 113 critically ill children,
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Figure 1 (See legend on next page.)
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Figure 1 Adaptive immune response. Adaptive immune function measured by ex vivo PHA-induced cytokine-production capacities within
48 hours of sepsis onset (A-D) were lower for children who went on to develop persistent or nosocomial infection (gray bars) compared with
sepsis children who recovered without infectious complication (white bars) and healthy controls (striped bars). For those children with day 7 data
available (E-H), ex vivo PHA-induced cytokine-production capacities for both groups tended to improve over time. Bars (A-D) and symbols (E-H)
represent median values, with error bars representing interquartile range throughout. Dashed lines and shaded areas (E-H) represent median and
interquartile ranges for healthy control subjects. (*P < 0.05; **P < 0.01; ***P < 0.001).
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nosocomial infection. Meanwhile, prolonged lymphope-
nia (ALC < 1,000 for longer than 1 week) was independ-
ently associated with the development of nosocomial
infection, multiple organ dysfunction, and mortality [28].
In a subsequent single-center study of 24 children with
sepsis-induced multiple organ dysfunction syndrome,
nonsurvivors demonstrated lower absolute lymphocyte
counts compared with survivors as early as 3 days after
the onset of MODS, although earlier time points were
not evaluated in this study [29]. In a multi-center study,
Wong et al. [18] evaluated genomic expression patterns
in 84 critically ill children with systemic inflammatory
response syndrome, sepsis, or septic shock, and demon-
strated significant downregulation of genes related to

































Figure 2 Innate immune response. Innate immune function
measured by ex vivo LPS-induced cytokine-production capacities
within 48 hours of sepsis onset were lower for sepsis patients
compared with healthy controls. Differences were not seen in early
innate immune function between sepsis children who developed
persistent or nosocomial infection and sepsis children who did not.
Bars and error bars represent median values and interquartile range
(**P < 0.01; ****P < 0.0001).patients as early as the first day of illness [18]. Subse-
quent studies similarly demonstrated downregulated
expression of genes involved in adaptive immunity in
children with septic shock [30,31]. Thus far, these analyses
have been limited to genomic-expression profiles and have
not directly evaluated lymphocyte function. Ours is the
first study to quantitate lymphocyte cytokine-production
capacity as a measure of adaptive immune function in crit-
ically ill children. In our study, ex vivo PHA-induced pro-
duction of both pro- and antiinflammatory cytokines from
isolated CD4+ T cells was decreased in sepsis patients
compared with healthy controls and was lowest in chil-
dren with sepsis who developed persistent or nosocomial
infection. These decreases were most apparent early in the
course of illness (within the first 48 hours of sepsis onset).
Temporal relations between innate and adaptive im-
munity are likely important. Previous adult studies sug-
gest that adaptive immune suppression in the setting of
sepsis may lag behind earlier alterations in innate immune
function [10,14]. In our study, we found much earlier evi-
dence of adaptive immune suppression, with the degree of
suppression being related to the risk of developing infec-
tious complications. Whether this may suggest a physio-
logic difference between adults and children or may reflect
differences in timing of presentation relative to the onset
of septic disease is unclear. It is notable that our work is in
agreement with the aforementioned genomic-based ana-
lyses of children with sepsis, which found alterations in
gene expression related to adaptive immunity evident on
the first day of illness [18].
Although early decreases were also seen in innate im-
mune function in our cohort, innate immune suppression
was not related to the development of persistent or noso-
comial infection. This is likely because the vast majority of
children recovered innate immune function within 7 days.
Indeed, in keeping with previous studies, the only two
children in the cohort with persistent severe innate im-
mune suppression were the only two mortalities in the co-
hort. Unfortunately, because of the small sample size and
few patients with persistent immune suppression, we are
unable to comment further on relationships between in-
nate and adaptive immune function over time. We view
this as an important avenue of future research.
Mechanisms of the observed adaptive immune suppres-
sion are unclear. Lymphopenia and lymphocyte apop-
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Figure 3 Absolute lymphocyte counts and regulatory T cells. Sepsis patients who went on to develop persistent or nosocomial infection
(gray bars) had lower absolute lymphocyte counts within 48 hours of sepsis onset (A) but not on day 7 of illness (B) compared with sepsis
patients who recovered without infectious complication and healthy controls (A). No differences were seen among groups in percentage of
regulatory T cells measured within 48 hours of sepsis onset (C) or over time (D). Bars (A, C) and symbols (B, D) represent median values, with
error bars representing interquartile range throughout. Dashed lines and shaded areas (B, D) represent median and interquartile ranges for
healthy control subjects (*P < 0.05; ***P < 0.001).
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sistent infection also demonstrated decreased absolute
lymphocyte counts early in their illness. Although we did
not directly measure lymphocyte apoptosis in this study, it
is notable that differences in cytokine-production capacity
were apparent despite using equal numbers of lympho-
cytes in our stimulation assays. This suggests that factors
in addition to lymphocyte cell death alone may contribute
to adaptive immune suppression in children with sepsis.
Treg are a subset of CD4+ T cells with immunosuppres-
sive function. Previous studies have implicated Treg in
sepsis-induced adaptive immune suppression in adults
[10,13,14,33]. More recent studies, however, have ques-
tioned the importance of Treg in the setting of sepsis
[15,34]. In agreement with these recent studies, our study
also failed to show significant differences in percentage ofTreg in children with sepsis compared with healthy con-
trols or in children who developed persistent or nosoco-
mial infection compared with those who did not. Likewise,
we did not see evidence for TH2 skewing by cytokine-
production profile, but rather cytokine-production capacity
was reduced across the board.
For some patients in the cohort, glucocorticoid use
may have contributed to adaptive immune suppression.
Interestingly, hydrocortisone use was not associated with
the development of persistent or nosocomial infection in
our cohort. Although the debate continues over hydro-
cortisone use in children with septic shock, it is import-
ant to consider that more powerful antiinflammatory
glucocorticoids (for example, dexamethasone or methyl-
prednisolone) may be used in sepsis patients to manage
acute comorbidities such as reactive airways disease and
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of adaptive immune suppression in the setting of sepsis
and the association between antiinflammatory glucocor-
ticoids and adverse outcomes in our cohort, we believe
this is an important area for future prospective study.
Our study has important limitations, including a small
sample size. Thus, we cannot perform multivariable ana-
lyses to account for other baseline differences between
groups that could have confounded our results. Our study
is also limited by the fact that many patients recovered be-
fore day 7 sampling. It is possible that we might have de-
tected greater differences between groups in both innate
and adaptive immune function in the subacute phase if day
7 samples were available for all patients. Likewise, with
only two sampling windows, we are unable to determine
patterns of immune function at other points in time. Last,
as we chose to compare sepsis children with healthy con-
trols, we cannot comment on the specificity of our findings
to septic shock. Adaptive immune suppression may also
occur in other critically ill pediatric populations, which we
view as an important area of future study.
Conclusions
This cohort of critically ill children with septic shock dem-
onstrated early adaptive immune suppression compared
with healthy children, with further suppression seen in
children who went on to develop infectious complications.
This was characterized by lower CD4+ T-cell cytokine-
production capacities and lymphopenia, but not by in-
creased percentage of regulatory T cells. Future studies are
needed to confirm these findings in a larger cohort of pa-
tients, to investigate potential mechanisms of adaptive im-
mune suppression in pediatric sepsis, and to understand
the interplay between innate and adaptive immune re-
sponses in children with sepsis.
Key messages
 CD4+ T cells isolated from children with septic
shock show decreased ability to produce both
pro- and antiinflammatory cytokines in response to
ex vivo stimulation.
 Among children with sepsis, suppressed CD4+ T-cell
cytokine-production capacity is associated with the
development of persistent or new nosocomial
infection.
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